재조합 인간 인터페론 알파

용도

• FeLV infection (Low dose)
• FeLV infection (High dose)
• FIV infection
• Chronic FHV-1 infections (Systemic)
• Chronic FHV-1 infections (Ophthalmic)
• Acute life-threatening FHV-1 infections in kittens
• Cutaneous T-cell lymphoma and severe cases of oral/cutaneous papillomas
• Immunostimulant for adjunctive treatment of dermatologic conditions (e.g., pododermatitis, papillomas, digital keratomas)

투여 방법

가능한 부작용

• Malaise
• Fever
• Allergic reactions
• Myelotoxicity (anemia, leukopenia, thrombocytopenia)
• Myalgia
• Neutralizing antibody formation (in cats, leading to loss of efficacy)
• Hepatotoxicity (reported in humans)
• Neurotoxicity (reported in humans)
• Flu-like syndrome (reported in humans)

주의사항 및 금기

• Feline Infectious Peritonitis (FIP) - low dose oral therapy is contraindicated
• Preexisting autoimmune disease
• Severe cardiac disease
• Severe pulmonary disease
• 'Brittle' diabetes
• CNS disorders
• Known hypersensitivity to the drug
• When used parenterally, carefully weigh the **risks versus benefits** in patients with preexisting autoimmune disease, severe cardiac or pulmonary disease, 'brittle' diabetes, Herpes infections, or CNS disorders. * **Pregnancy**: Safety is not established (FDA Category C). High parenteral doses in monkeys increased abortifacient activity. * **Antibody Formation**: Prolonged parenteral use in cats (3-7 weeks) often leads to neutralizing antibodies, rendering the drug ineffective.

약물 상호작용

• Acyclovir: Additive or synergistic antiviral effects may occur.
• Zidovudine (AZT): Additive or synergistic antiviral effects may occur.
• Vidarabine: Increased toxicities may occur without synergistic antiviral effects.

자주 묻는 질문